All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Depression, Anxiety, and Quality of Life among Patients with Psoriasis: Prevalence, and Associated Factors

DOI: 10.4236/oalib.1109989, PP. 1-14

Subject Areas: Psychiatry & Psychology

Keywords: Depression, Anxiety, Quality of Life, Psoriasis, HADS, SF-12

Full-Text   Cite this paper   Add to My Lib


Background: Like many chronic skin diseases, psoriasis has a psychological impact on the sufferer and a huge impact on quality of life. The aim of the study is to estimate the prevalence of depression and anxiety among patients suffering from psoriasis in a region of Morocco, and to identify sociodemo-graphic, disease-related, and quality of life associated factors. Materials and Methods: A cross-sectional study was carried out in the dermatology department of the Hassan II University Hospital in Fez between September 2019 and December 2020 on patients with psoriasis. The Hospital Anxiety and Depression Scale were used to measure depression and anxiety, and the 12-item Short Form survey to measure Quality of Life. A multivariate analysis was used to determine associated factors. Results: Results: A total of 133 participants were included, with men slightly predominant at 70 (52.6%). Of the participants, 67.7% were aged 35 years or older, and duration of psoriasis greater than 3 years was predominant at 79.7%. The prevalence of depression was 28.6% with a 95% CI (20.9 - 36.2), and anxiety was 41.4% with a 95% CI (33.0 - 49.7). The mean scores for mental (MCS-12) and physical (PCS-12) quality of life were 36.4 ± 7.0 and 35.9 ± 5.8, respectively. Depression was associated with advanced age, female gender, married status, high affected body surface area, and low MCS-12, while anxiety was associated with advanced age, pruritus, and low MCS-12. Conclusion: Our results suggest that it is important to establish the detection of mental health disorders and assess the impact of psoriasis on patients’ quality of life, particularly in terms of mental quality, as part of psoriasis care.

Cite this paper

Maiouak, M. , Harch, I. E. , Chakri, I. , Benmaamar, S. , Bay, H. B. , Otmani, N. E. , Tachfouti, N. , Mernissi, F. Z. and Fakir, S. E. (2023). Depression, Anxiety, and Quality of Life among Patients with Psoriasis: Prevalence, and Associated Factors. Open Access Library Journal, 10, e9989. doi:


[1]  Hertz, A. (2014) Psoríase na infancia. Revista HUPE, Rio de Janeiro, 13, 40-49.
[2]  Romiti, R., Amone, M., Menter, A. and Miot, H.A. (2017) Prevalence of Psoriasis in Brazil—A Geographical Survey. The International Journal of Dermatology, 56, e167-e168.
[3]  Gibbs, S. (1996) Skin Disease and Socioeconomic Conditions in Rural Africa: Tanzania. International Journal of Dermatology, 35, 633-639.
[4]  Danielsen, K., Olsen, A.O., Wilsgaard, T. and Furberg, A.S. (2013) Is the Prevalence of Psoriasis Increasing? A 30-Year Follow-Up of a Population-Based Cohort. The British Journal of Dermatology, 168, 1303-1310.
[5]  De Deyn, M., Guerin, C., Moloney, K., Roden, Y. and Nath, N. (2015) Should Psoriasis Patients be Screened for Heart Disease. Trinity Student Medical Journal, 16, 23-28.
[6]  Takeshita, J., Grewal, S., Langan, S.M., Mehta, N.N., Ogdie, A., Van Voorhees, A.S., et al. (2017) Psoriasis and Comorbid Diseases: Epidemiology. Journal of the American Academy of Dermatology, 76, 377-390.
[7]  Silva, K.S. and Silva, E.A.T. (2007) Psoriasis and Its Relation with Psychological Aspects, Stress, and Life Events. Estudos de Psicologia (Campinas), 24, 257-266.
[8]  Chamoun, A., Goudetsidis, L., Poot, F., Bourdeaud’hui, F. and Titeca, G. (2005) Psoriasis et dépression. AMUB.
[9]  Bakar, R.S., Jaapar, S.Z.S., Azmi, A.F. and Aun, Y.C. (2021) Depression and Anxiety among Patients with Psoriasis: A Correlation with Quality of Life and Associated Factors. Journal of Taibah University Medical Sciences, 16, 491-496.
[10]  Picardi, A., Abeni, D., Melchi, C.F., Puddu, P. and Pasquini, P. (2000) Psychiatric Morbidity in Dermatological Outpatients: An Issue to Be Recognized. British Journal of Dermatology, 143, 983-991.
[11]  Richards, H.L., Fortune, D.G., Griffiths, C.E. and Main, C.J. (2001) The Contribution of Perceptions of Stigmatisation to Disability in Patients with Psoriasis. Journal of Psychosomatic Research, 50, 11-15.
[12]  Rajalakshmi, S., Sathiyarajeswaran, P. and Samraj, K. (2019) An Open Comparative Clinical Trial to Evaluate the Efficacy and Safety of Siddha Drugs Panchamuga Chendhuram and Kundavaadhi Thailam in Psoriasis. International Journal of Research in Ayurveda and Pharmacy, 10, 77-82.
[13]  Szepietowski, J., Adamski, Z., Chodorowska, G., Gliński, W., Kaszuba, A., Placek, W., Rudnicka, L. and Reich. A. (2012) Diagnostics and Treatment of Psoriasis Vulgaris: Guidelines of the Polish Dermatological Society. Part I: Mild Psoriasis, Psoriasis in Children. Przeglad Dermatologiczny, 99, 83-96.
[14]  Zigmond, A.S. and Snaith, R.P. (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica, 67, 361-370.
[15]  Terkawi, A.S., Tsang, S., AlKahtani, G.J., Al-Mousa, S.H., Al Musaed, S., AlZoraigi, U.S., et al. (2017) Development and Validation of Arabic Version of the Hospital Anxiety and Depression Scale. Saudi Journal of Anesthesia, 11, 8-11.
[16]  Ware, J.E. and Sherbourne, C.D. (1992) The MOS 36-Item Short-Form Health Survey (SF-36) I. Conceptual Framework and Item Selection. Medical Care, 30, 473-483.
[17]  Obtel, M., Rhazi, K.E., Nejjari, C., Elhold, S., Benjelloune, M.C., Gnatiuc, L. and Nejjari, C. (2013) Cross-Cultural Adaptation of the 12-Item Short-Form Survey Instrument in a Moroccan Representative Survey: Original Research. Southern African Journal of Epidemiology and Infection, 28, 166-171.
[18]  Pollo, C.F., Miot, H.A., Matos, T.D., Souza, J.M., Jorge, M.F.S., Miot, L.D.B., et al. (2020) Prevalence and Factors Associated with Depression and Anxiety in Patients with Psoriasis. Journal of Clinical Nursing, 30, 572-580.
[19]  McDonough, E., Ayearst, R., Eder, L., Chandran, V., Rosen, C.F., Thavaneswaran, A. and Gladman, D.D. (2014) Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors. The Journal of Rheumatology, 41, 887-896.
[20]  Daudén, E., Griffiths, C.E.M., Ortonne, J.-P., Kragballe, K., Molta, C.T., Robert-son, D., Pedersen, R., Estojak, J. and Boggs, R. (2009) Improvements in Patient-Reported Outcomes in Moderate-to-Severe Psoriasis Patients Receiving Continuous or Paused Etanercept Treatment over 54 Weeks: The CRYSTEL Study. Journal of the European Academy of Dermatology and Venereology, 23, 1374-1382.
[21]  Langley, R.G., Feldman, S.R., Han, C., Schenkel, B., Szapary, P., Hsu, M.-C., et al. (2010) Ustekinumab Significantly Improves Symptoms of Anxiety, Depression, and Skin-Related Quality of Life in Patients with Moderate-to-Severe Psoriasis: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. Journal of the American Academy of Dermatology, 63, 457-465.
[22]  Hawes, M.T., Szenczy, A.K., Klein, D.N., Hajcak, G. and Nelson, B.D. (2021) Increases in Depression and Anxiety Symptoms in Adolescents and Young Adults during the Covid-19 Pandemic. Psychological Medicine, 52, 3222-3230.
[23]  Choi, E.P.H., Hui, B.P.H. and Wan, E.Y.F. (2020) Depression and Anxiety in Hong Kong during Covid-19. IJERPH, 17, Article 3740.
[24]  Lamb, R.C., Matcham, F., Turner, M.A., Rayner, L., Simpson, A., Hotopf, M., Barker, J.N.W.N., Jackson, K. and Smith, C.H. (2017) Screening for Anxiety and Depression in People with Psoriasis: A Cross-Sectional Study in a Tertiary Referral Setting. British Journal of Dermatology, 176, 1028-1034.
[25]  Esposito, M., Saraceno, R., Giunta, A., Maccarone, M. and Chimenti, S. (2006) An Italian Study on Psoriasis and Depression. Dermatology, 212, 123-127.
[26]  Golpour, M., Hosseini, S.H., Khademloo, M., Ghasemi, M., Ebadi, A., Koohkan, F. and Shahmohammadi, S. (2012) Depression and Anxiety Disorders among Patients with Psoriasis: A Hospital-Based Case-Control Study. Dermatology Research and Practice, 2012, Article ID: 381905.
[27]  Yang, Y., Koh, D., Khoo, L., Nyunt, S.Z., Ng, V. and Goh, C.L. (2005) The Psoriasis Disability Index in Chinese Patients: Contribution of Clinical and Psychological Variables. International Journal of Dermatology, 44, 925-929.
[28]  Tee, S.I., Lim, Z.V., Theng, C.T., Chan, K.L. and Giam, Y.C. (2016) A Prospective Cross-Sectional Study of Anxiety and Depression in Patients with Psoriasis in Singapore. Journal of the European Academy of Dermatology and Venereology, 30, 1159-1164.
[29]  Nasreen, S., Ahmed, I. and Effendi, S. (2008) Frequency and Magnitude of Anxiety and Depression in Patients with Psoriasis Vulgaris. Journal of the College of Physicians and Surgeons-Pakistan, 18, 397-400.
[30]  Lakshmy, S., Balasundaram, S., Sarkar, S., Audhya, M. and Subramaniam E. (2015) A Cross-Sectional Study of Prevalence and Implications of Depression and Anxiety in Psoriasis. Indian Journal of Psychological Medicine, 37, 434-440.
[31]  Fortune, D.G., Richards, H.L., Griffiths, C.E.M. and Main, C.J. (2002) Psychological Stress, Distress and Disability in Patients with Psoriasis: Consensus and Variation in the Contribution of Illness Perceptions, Coping and Alexithymia. British Journal of Clinical Psychology, 41, 157-174.
[32]  Sahi, F.M., Masood, A., Danawar, N.A., Mekaiel, A., Malik, B.H., Sahi, F.M., et al. (2020) Association between Psoriasis and Depression: A Traditional Review. Cureus, 12, e9780.
[33]  Lakuta, P. and Przybyla-Basista, H. (2017) Toward a Better Understanding of Social Anxiety and Depression in Psoriasis Patients: The Role of Determinants, Mediators, and Moderators. Journal of Psychosomatic Research, 94, 32-38.
[34]  Akay, A., Pekcanlar, A., Bozdag, K.E., Altintas, L. and Karaman, A. (2002) Assessment of Depression in Subjects with Psoriasis Vulgaris and Lichen Planus. Journal of the European Academy of Dermatology and Venereology, 16, 347-352.
[35]  Silva, N., Augustin, M., Hilbring, C, Stülpnagel, C.C.B. and Sommer, R. (2022) Psychological (co)morbidity in Patients with Psoriasis: The Impact of Pruritus and Anogenital Involvement on Symptoms of Depression and Anxiety and on Body Dysmorphic Concerns—A Cross-Sectional Study. BMJ Open, 12, e055477.
[36]  Grozdev, I., Kast, D., Cao, L., Carlson, D., Pujari, P., Schmotzer, B., et al. (2012) Physical and Mental Impact of Psoriasis Severity as Measured by the Compact Short Form-12 Health Survey (SF-12) Quality of Life Tool. Journal of Investigative Dermatology, 132, 1111-1116.
[37]  Martínez-Ortega, J.M., Nogueras, P., Muñoz-Negro, J.E., Gutiérrez-Rojas, L., González-Domenech, P. and Gurpegui, M. (2019) Quality of Life, Anxiety and Depressive Symptoms in Patients with Psoriasis: A Case-Control Study. Journal of Psychosomatic Research, 124, Article ID: 109780.


comments powered by Disqus

Contact Us


WhatsApp +8615387084133

WeChat 1538708413